(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday. Dolsten ...
On Friday, Novo Nordisk A/S' (NYSE: NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.
Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results